Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer’s disease

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F17%3A73585001" target="_blank" >RIV/61989592:15110/17:73585001 - isvavai.cz</a>

Result on the web

<a href="https://link.springer.com/article/10.1007%2Fs00018-017-2574-1" target="_blank" >https://link.springer.com/article/10.1007%2Fs00018-017-2574-1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00018-017-2574-1" target="_blank" >10.1007/s00018-017-2574-1</a>

Result language

angličtina

Original language name

Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer’s disease

Original language description

Alzheimer&apos;s disease (AD) is a progressive neurodegenerative disorder that affects normal functions of the brain. Currently, AD is one of the leading causes of death in developed countries and the only one of the top ten diseases without a means to prevent, cure, or significantly slow down its progression. Therefore, newer therapeutic concepts are urgently needed to improve survival and the quality of life of AD patients. Microtubule affinity-regulating kinases (MARKs) regulate tau-microtubule binding and play a crucial role in neurons. However, their role in hyperphosphorylation of tau makes them potential druggable target for AD therapy. Despite the relevance of MARKs in AD pathogenesis, only a few small molecules are known to have anti-MARK activity and not much has been done to progress these compounds into therapeutic candidates. But given the diverse role of MARKs, the specificity of novel inhibitors is imperative for their successful translation from bench to bedside. In this regard, a recent co-crystal structure of MARK4 in association with a pyrazolopyrimidine-based inhibitor offers a potential scaffold for the development of more specific MARK inhibitors. In this manuscript, we review the biological role of MARKs in health and disease, and draw attention to the largely unexplored area of MARK inhibitors for AD.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Cellular and Molecular Life Sciences

ISSN

1420-682X

e-ISSN

—

Volume of the periodical

74

Issue of the periodical within the volume

22

Country of publishing house

CH - SWITZERLAND

Number of pages

11

Pages from-to

4159-4169

UT code for WoS article

000412895200007

EID of the result in the Scopus database

—